MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN

Jean-Frédéric Colombel  ¹     Mark T. Osterman  ²     Patricio Ibáñez  ³     Severine Vermeire  ⁴     Peter Irving  ⁵     Sean Gardiner  ⁶     Susan B. Connelly  ⁷     Rajiv Mundayat  ⁷     Nervin Lawendy  ⁷     Chinyu Su  ⁷     Walter Reinisch  ^8    
1 Department of Gastroenterology, New York, NY, United States
² University of Pennsylvania, Philadelphia, PA, United States
³ Gastroenterology Department, Santiago, Chile
⁴ Department of Gastroenterology, Leuven, Belgium
⁵ IBD Unit, London, United Kingdom
⁶ Pfizer Inc, New York, NY, United States
⁷ Pfizer Inc, Collegeville, PA, United States
⁸ Department of Internal Medicine III, Vienna, Austria

Topic
IBD

Session
IBD: Clinical trials II (small molecules)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)